What Is a PitNET? Pituitary Adenoma Pathology Explained
At a Glance
A PitNET (Pituitary Neuroendocrine Tumor) is simply the updated medical name for a pituitary adenoma. The new name reflects the tumor's biology more accurately, but it does not mean your diagnosis has changed to cancer. The vast majority of PitNETs remain benign and highly treatable.
In this answer
3 sections
When you look at your pathology report, you might see the term PitNET (Pituitary Neuroendocrine Tumor) instead of “pituitary adenoma.” Seeing an unfamiliar term—especially one that includes the word “tumor”—can be startling.
If you are wondering whether this means your diagnosis has changed to cancer, take a deep breath: it does not [1]. A PitNET is simply the new, more medically accurate name for a pituitary adenoma [2]. The majority of these tumors remain benign, meaning they are not cancer [3][4].
Why Did the Name Change?
Under the updated 2022 World Health Organization (WHO) classification of pituitary tumors, the long-standing term “pituitary adenoma” was officially replaced with “Pituitary Neuroendocrine Tumor” or PitNET [2][1].
Doctors made this change for a few key reasons:
- Accuracy of Cell Types: The new name better describes the actual biology of the cells involved [5]. Pituitary tumors develop from neuroendocrine cells, which are cells that normally bridge the nervous and endocrine systems. Modern testing shows that the genetic profile of these cells is much closer to other neuroendocrine tumors than to standard “adenomas” found elsewhere in the body [6]. (Note: Even though the cells are “neuroendocrine” by nature, your specific tumor might still be “non-functioning,” meaning it does not actually release excess hormones into your bloodstream.)
- Predicting Tumor Behavior: While most pituitary tumors are benign and slow-growing, a small number can grow more quickly or be harder to treat [7]. The word “adenoma” typically implies a strictly harmless mass, which doesn’t completely capture the fact that some of these tumors can press on nearby structures (like the optic nerve) or recur after treatment [1][3].
What This Means for Your Pathology Results
Having the word “PitNET” on your pathology report does not mean your condition is suddenly more dangerous [2]. It simply gives your medical team better tools to understand your specific tumor.
Under the new WHO classification, pathologists test the tumor tissue for specific markers called transcription factors [8]. These markers—which often appear on your report as acronyms like PIT-1, T-PIT, or SF-1—tell your doctor exactly which type of cell in the pituitary gland the tumor grew from [9].
Knowing the exact lineage of your PitNET helps your doctors:
- Predict how the tumor might behave over time [10].
- Determine the most effective personalized treatment plan [11].
- Understand the best approach for management. For example, certain functioning PitNETs might respond to medication, whereas non-functioning PitNETs typically require surgery or careful observation [12].
The Bottom Line
A PitNET is a pituitary adenoma. The medical community updated the name to be more scientifically precise, not because your diagnosis has worsened [5][2]. The vast majority of PitNETs are benign, highly treatable, and not considered cancer [3].
Common questions in this guide
Is a PitNET cancer?
Why did my doctor call it a PitNET instead of a pituitary adenoma?
What do markers like PIT-1, T-PIT, or SF-1 mean on my pathology report?
Will my non-functioning PitNET require treatment?
What does an elevated Ki-67 index mean on my report?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which specific cell lineage or transcription factor (such as SF-1, T-PIT, or PIT-1) was identified in my PitNET pathology report?
- 2.Does my pathology report show any markers, like an elevated Ki-67 index, that suggest this tumor might grow quickly or recur?
- 3.How does the specific lineage and subtype of my PitNET impact my long-term monitoring and imaging schedule?
- 4.Was there any evidence of invasion into surrounding structures (like the cavernous sinus or bone) noted during surgery or on my pathology report?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (12)
- 1
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.
Asa SL, Casar-Borota O, Chanson P, et al.
Endocrine-related cancer 2017; (24(4)):C5-C8 doi:10.1530/ERC-17-0004.
PMID: 28264912 - 2
Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.
Tapoi DA, Popa ML, Tanase C, et al.
Cancers 2023; (15(21)) doi:10.3390/cancers15215301.
PMID: 37958474 - 3
Advancements in Molecular Diagnosis and Pharmacotherapeutic Strategies for Invasive Pituitary Adenomas.
Xu D, Wang L, Zheng M
Immunity, inflammation and disease 2024; (12(12)):e70098 doi:10.1002/iid3.70098.
PMID: 39688352 - 4
Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
Lee CH
Brain tumor research and treatment 2023; (11(3)):173-176 doi:10.14791/btrt.2023.0015.
PMID: 37550816 - 5
Pituitary Neuroendocrine Tumor or Pituitary Adenoma? Let's Ask the Epigenome!
Dottermusch M
Endocrine pathology 2025; (36(1)):35 doi:10.1007/s12022-025-09879-8.
PMID: 41060331 - 6
Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M, Schüller U, Hagel C, Saeger W
Neuropathology and applied neurobiology 2023; (49(1)):e12870 doi:10.1111/nan.12870.
PMID: 36527335 - 7
Transformation of Lactotroph Pituitary Adenoma to Metastatic Pituitary Carcinoma: A Case Report.
Christensen K, Mrvoljak M, Njoku CL, et al.
Cureus 2025; (17(10)):e95326 doi:10.7759/cureus.95326.
PMID: 41293361 - 8
A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS, Ho RS, Ho G, et al.
Frontiers in endocrinology 2024; (15()):1368944 doi:10.3389/fendo.2024.1368944.
PMID: 38756997 - 9
Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
Zhang Q, Yao B, Long X, et al.
Cell reports. Medicine 2023; (4(2)):100934 doi:10.1016/j.xcrm.2023.100934.
PMID: 36754052 - 10
Current understanding of the role of DNA methylation in pituitary neuroendocrine tumors.
Peterson R, Cote DJ, Zada G
Neuro-oncology advances 2025; (7(Suppl 1)):i2-i9 doi:10.1093/noajnl/vdae149.
PMID: 40718392 - 11
Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X, Tang H, Bie Z, et al.
Neurosurgery 2024; doi:10.1227/neu.0000000000002846.
PMID: 38289085 - 12
Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.
Wen S, Li C, Zhan X
The EPMA journal 2022; (13(1)):9-37 doi:10.1007/s13167-022-00274-5.
PMID: 35273657
This page is for informational purposes only and does not replace professional medical advice. Always consult your endocrinologist, neurosurgeon, or pathologist to interpret your specific PitNET pathology results.
Get notified when new evidence is published on Non-functioning pituitary adenoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.